Chiropractors in Milton, WA Accepting Medicare

5 Chiropractors found. Showing 1 - 5

Surprise Lake Chiropractic Chiropractor Medicare: Medicare Enrolled Practice Location: 2748 Milton Way, Suite 211, Milton, WA 98354 Phone: 253-952-0302

Surprise Lake Chiropractic, Inc Pc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 724 Meridian E Ste 1, Milton, WA 98354 Phone: 253-952-0302    Fax: 253-952-0307

Dr. Jennie Bonfiglio, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 724 Meridian E Ste 1, Milton, WA 98354 Phone: 253-952-0302    Fax: 253-952-0307

Dr. Ida M Rogers, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2748 Milton Way, Ste 211, Milton, WA 98354 Phone: 253-952-0302    Fax: 253-952-0307

Surprise Lake Chiropractic Inc Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2748 Milton Way, Suite 211, Milton, WA 98354 Phone: 253-952-0302    Fax: 253-952-0307

News Archive

Physicians launch international advocacy campaign on TB

Physicians across the globe are coming together to advocate for a large, underrepresented patient population - those suffering from tuberculosis. On World TB Day, March 24th, a team of physician and researchers led by Case Western Reserve University School of Medicine's Tuberculosis Research Unit will nationally launch "I am TB," an international advocacy campaign aimed at reducing stigma among patients with TB and those at risk for the disease.

Alcohol linked to premature births

Australian researchers have found a link between alcohol and premature births and say women should limit their alcohol intake during pregnancy, especially in the first three months.

Individual dental patterns are as reliable as DNA tests, say researchers

Researchers from the University of Granada have shown that a person's dental patterns can be used as proof of their identity with the same degree of reliability as DNA testing, the method that forensic police use to reveal the identity of dead bodies. The researchers came to their conclusion after analyzing the dental patterns of more than 3,000 people.

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics LLC today highlighted results from a sub-analysis of the Phase III RESONATE™ (PCYC-1112) trial, which found that previously-treated patients with chronic lymphocytic leukemia (CLL) who adhered to the recommended 420 mg dose of IMBRUVICA® (ibrutinib) experienced improved progression-free survival (PFS; the primary endpoint) as assessed by an Independent Review Committee (IRC), compared to patients who took lower doses or missed doses, regardless of high-risk genetic factors.

Read more Medical News

› Verified 8 days ago